AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$NTRA

Chapman Steven Leonard sold $545K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,698 shares of Natera, Inc. (NTRA) at $320.99 ($0.55M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Sep 4, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale is modest in size and likely to have limited price impact, but may be noted by short‑term traders.

02

Market read

Routine insider sale with modest size; low trading relevance.

03

What to watch

CEO retains a large stake (98,199 shares), indicating continued confidence.

Relevance 4/10Novelty 3/10Timing: filing date 2026‑09‑01

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

CEO Steven Leonard sold 1,698 shares for $545K via a 10b5‑1 plan, reducing his stake to 98,199 shares.

Expected impact

Potential short‑term pressure on NTRA, likely limited to a few basis points.

Evidence & confidence

Sale is under $1M and typical for a 10b5‑1 plan; market may view it as neutral to slightly negative.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector‑wide.

Regional

No regional effect beyond NTRA shareholders.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Individual
    Steven Leonard Chapman

    CEO and President of Natera, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

SEP 9
$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

yahoo.com2 min
SEP 2
$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min